A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

New Hope in Combatting MRSA Superbug in Hospital Infections

The seven-month study in an urban medical-surgical ICU highlights the impact of ActivePure Medical’s proactive, continuous, disinfection technology on HAIs

ActivePure, an infection prevention technology company that provides continuous, whole-department disinfection technology, today announced the publication of their study on Methicillin-Resistant Staphylococcus aureus (MRSA),surface microbial burden, and Healthcare-Associated Infections (HAIs). 

Healthcare-Onset MRSA (HO-MRSA) bacteremia infections had a statistically significant 100% decrease (and in fact were eliminated during the trial period) when compared to the same time frame a year prior and the immediate six months prior. This self-operating solution was implemented department-wide in the ICU, and no changes were made or required to the hospital’s cleaning and disinfection practices, trainings or schedules. The study also concluded that the use of ActivePure’s Advanced Photocatalysis technology in a Medical-Surgical Intensive Care Unit (ICU) resulted in a statistically significant 98% reduction of the levels of MRSA surface burden from baseline to final post-activation test. 

The study is now available via the Open Forum Infectious Diseases a publication of the Infectious Diseases Society of America (IDSA), and can be found here. 

“Keeping patients and team members safe is the top priority for infection prevention and control, and as HAIs in healthcare continue to rise and occur. I am proud to highlight the improvements we made with ActivePure Medical,” said Lori Berthelot, RN, BSN, CIC, study co-author and supervisor of infection control at the study hospital. 

System Director of Infection Prevention and Control for the study hospital and Study Co-author, Beth Ann Lambert, MS, CIC, added, “It is such an honor to be able to share our experience and encourage others that you can improve the environment of care even during these challenging times of a pandemic and labor shortage crisis.”  

The primary author of the study is Caitlin Stowe, MPH, CPC, CIC, CPHQ, VA-BC and vice president of clinical affairs and medical liaison of ActivePure Medical. Additional co-authors of the abstract include Katherine Baumgarten, MD and Nattie Leger, MSN, RN, LSSBB.  

“The last few years have exposed the risks of infection by spotlighting the issues that already existed, raising their visibility, but also the 21st century solutions that are now available. The results of this study have opened the door for healthcare facilities to protect their areas prone to the spread of healthcare-associated infections, like MRSA, with proven, real-world results,” said Deborah Birx, M.D., chief medical and science advisor of ActivePure Technologies. “ActivePure Medical has worked diligently to prove the efficacy of the technology through extensive testing and FDA clearance. All this work has shown that it is an essential solution for today to address aerosol pathogens like SAR-CoV-2 to multidrug-resistant bacteria and fungi.” 

To read the complete study or learn about ActivePure Medical, please visit www.ActivePureMedical.com/MRSA

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy